Gabapentin
Product Images NDC 66336-567

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 66336-567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0439-xx (Ndc 66336 0439 Xx Westward)

Label for Gabapentin 300 mg capsules by Dispensing Solutions, Inc. The label includes the product name, strength, dosage form, and NDC 66336-0439-XX, with a note that each capsule contains 300 mg of Gabapentin USP. It is marked RX only and indicates storage temperature and warnings. The label also features barcodes, lot information as 'SAMPLE,' and distributor information from West-Ward Pharmaceutical Corp.*

FDA Label Image

Ndc 66336-0567-xx (Ndc 66336 0567 Xx West Ward)

Label for Gabapentin 100 mg capsules from Dispensing Solutions, Inc. The label includes the NDC 66336-0567-XX and product number 783-XX. It has warnings to keep out of children's reach and storage instructions at 68°-77°F. Directions note potential dizziness or drowsiness and a warning not to take with Maalox. The label also indicates the product is distributed by West-Ward Pharmaceutical Corp., Eatontown, NJ.*

FDA Label Image

Structural Formula (Gabapentin Capsules 1)

Chemical structure diagram of gabapentin, depicting its cyclohexane ring with attached amino and carboxyl functional groups.*

FDA Label Image

Figure 1. Weekly Mean Pain Score (observed Cases In Itt Population): Study 1 (Gabapentin Capsules 2)

A line graph depicting mean pain scores over an 8-week period for two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores. Gabapentin shows a decreasing trend in pain score compared to placebo, with statistical significance (p < 0.01) indicated at multiple points.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Capsules 3)

A line graph showing mean pain score over 7 weeks comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Both Gabapentin groups demonstrate a decrease in pain scores compared to placebo over time.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Capsules 4)

A bar chart comparing the percentage of responders at endpoint between placebo (PBO) and Gabapentin (GBP) at various doses in two studies. Study 1 shows PBO at 12%, GBP 3600 at 29%. Study 2 shows PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%. Statistical significance levels (p < 0.01 and p < 0.001) are indicated for some comparisons.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (Gabapentin Capsules 5)

A scatter plot comparing percentage differences across three studies (Study a, Study b, Study c) at various daily doses of Gabapentin in milligrams (600, 900, 1200, and 1800 mg). The y-axis shows percentage difference values, and different symbols represent each study's data points for each dose level.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.